Arturo Sala

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3756185/publications.pdf

Version: 2024-02-01

53 papers	2,121 citations	201674 27 h-index	233421 45 g-index
55 all docs	55 docs citations	55 times ranked	2565 citing authors

#	Article	IF	Citations
1	MYB oncoproteins: emerging players and potential therapeutic targets in human cancer. Oncogenesis, 2021, 10, 19.	4.9	79
2	Integrinâ€Targeted, Short Interfering RNA Nanocomplexes for Neuroblastoma Tumorâ€Specific Delivery Achieve MYCN Silencing with Improved Survival. Advanced Functional Materials, 2021, 31, 2104843.	14.9	12
3	MYC regulates metabolism through vesicular transfer of glycolytic kinases. Open Biology, 2021, 11, 210276.	3.6	5
4	Targeting Vesicular LGALS3BP by an Antibody-Drug Conjugate as Novel Therapeutic Strategy for Neuroblastoma. Cancers, 2020, 12, 2989.	3.7	16
5	ATR is a MYB regulated gene and potential therapeutic target in adenoid cystic carcinoma. Oncogenesis, 2020, 9, 5.	4.9	37
6	Repurposing a psychoactive drug for children with cancer: p27Kip1-dependent inhibition of metastatic neuroblastomas by Prozac. Oncogenesis, 2020, 9, 3.	4.9	5
7	Engineered human mesenchymal stem cells for neuroblastoma therapeutics. Oncology Reports, 2019, 42, 35-42.	2.6	12
8	Abstract 238: Therapeutic activity of the non-internalizing antibody drug conjugate 1959-sss/DM3 targeting galectin3-binding protein in human neuroblastoma. , 2019, , .		1
9	Abstract 238: Therapeutic activity of the non-internalizing antibody drug conjugate 1959-sss/DM3 targeting galectin3-binding protein in human neuroblastoma. , 2019, , .		0
10	Functional and prognostic significance of the genomic amplification of frizzled 6 (FZD6) in breast cancer. Journal of Pathology, 2017, 241, 350-361.	4.5	66
11	Generation of a novel Antibody-Drug Conjugate targeting endosialin: potent and durable antitumor response in sarcoma. Oncotarget, 2017, 8, 60368-60377.	1.8	13
12	Cutaneous cylindroma: it's all about MYB. Journal of Pathology, 2016, 239, 391-393.	4.5	11
13	A Promyelocytic Leukemia Proteinâ€“Thrombospondin-2 Axis and the Risk of Relapse in Neuroblastoma. Clinical Cancer Research, 2016, 22, 3398-3409.	7.0	8
14	Editorial: Targeting MYCN in Pediatric Cancers. Frontiers in Oncology, 2015, 4, 330.	2.8	4
15	Identification and Pharmacological Inactivation of the MYCN Gene Network as a Therapeutic Strategy for Neuroblastic Tumor Cells. Journal of Biological Chemistry, 2015, 290, 2198-2212.	3.4	43
16	What football can teach science. Nature, 2014, 516, 329-329.	27.8	3
17	Polyphenol E Enhances the Antitumor Immune Response in Neuroblastoma by Inactivating Myeloid Suppressor Cells. Clinical Cancer Research, 2013, 19, 1116-1125.	7.0	74
18	Catechins and antitumor immunity. OncoImmunology, 2013, 2, e24443.	4.6	8

#	Article	IF	Citations
19	Physical Interaction between MYCN Oncogene and Polycomb Repressive Complex 2 (PRC2) in Neuroblastoma. Journal of Biological Chemistry, 2013, 288, 8332-8341.	3.4	77
20	c-MYB and TGFÎ²: EMTâ€™s dynamic duo in breast cancer. Cell Cycle, 2012, 11, 17-17.	2.6	16
21	A chemical screen identifies the chemotherapeutic drug topotecan as a specific inhibitor of the B-MYB/MYCN axis in neuroblastoma. Oncotarget, 2012, 3, 535-545.	1.8	16
22	Neuroblastoma: Role of Clusterin as a Tumor Suppressor Gene. Pediatric Cancer, 2012, , 169-176.	0.0	0
23	The tumour-suppressive function of CLU is explained by its localisation and interaction with HSP60. Cell Death and Disease, 2011, 2, e219-e219.	6.3	37
24	Frizzled receptor 6 marks rare, highly tumourigenic stem-like cells in mouse and human neuroblastomas. Oncotarget, 2011, 2, 976-983.	1.8	68
25	Addiction of MYCN amplified tumours to B-MYB underscores a reciprocal regulatory loop. Oncotarget, 2010, 1, 278-88.	1.8	27
26	Addiction of MYCN Amplified Tumours to B-MYB Underscores a Reciprocal Regulatory Loop. Oncotarget, 2010, 1, 278-288.	1.8	29
27	Regulation of CLU Gene Expression by Oncogenes and Epigenetic Factors. Advances in Cancer Research, 2009, 105, 115-132.	5.0	40
28	Clusterin, a Haploinsufficient Tumor Suppressor Gene in Neuroblastomas. Journal of the National Cancer Institute, 2009, 101, 663-677.	6.3	87
29	Genetic inactivation of ApoJ/clusterin: effects on prostate tumourigenesis and metastatic spread. Oncogene, 2009, 28, 4344-4352.	5.9	42
30	Isolation and functional assessment of common, polymorphic variants of the B-MYB proto-oncogene associated with a reduced cancer risk. Oncogene, 2008, 27, 2929-2933.	5.9	12
31	B-MYB is hypophosphorylated and resistant to degradation in neuroblastoma: Implications for cell survival. Blood Cells, Molecules, and Diseases, 2007, 39, 263-271.	1.4	11
32	Ca2+ depletion induces nuclear clusterin, a novel effector of apoptosis in immortalized human prostate cells. Cell Death and Differentiation, 2005, 12, 101-104.	11.2	44
33	Temperature-dependent Modification and Activation of B-MYB. Journal of Biological Chemistry, 2005, 280, 15628-15634.	3.4	26
34	B-MYB, a transcription factor implicated in regulating cell cycle, apoptosis and cancer. European Journal of Cancer, 2005, 41, 2479-2484.	2.8	136
35	B-Myb acts as a repressor of human COL1A1 collagen gene expression by interacting with Sp1 and CBF factors in scleroderma fibroblasts. Biochemical Journal, 2004, 378, 609-616.	3.7	17
36	DNA damage or growth factor withdrawal does not evoke activation of MYB transcription factors in neuronal cancer cell lines. Neuroscience Letters, 2003, 336, 163-166.	2.1	2

#	Article	IF	Citations
37	Essential Requirement of Apolipoprotein J (Clusterin) Signaling for IÎºB Expression and Regulation of NF-ÎºB Activity. Journal of Biological Chemistry, 2003, 278, 38214-38219.	3.4	121
38	A challenge for research in Italy: to raise the dead. Nature, 2001, 414, 581-581.	27.8	0
39	PARP co-activates B-MYB through enhanced phosphorylation at cyclin/cdk2 sites. Oncogene, 2001, 20, 8167-8174.	5.9	27
40	Physical interaction between CDK9 and B-Myb results in suppression of B-Myb gene autoregulation. Oncogene, 2000, 19, 373-379.	5.9	43
41	Poly(ADP-ribose) Polymerase Is a B-MYB Coactivator. Journal of Biological Chemistry, 2000, 275, 10692-10696.	3.4	117
42	Direct Transactivation of the Anti-apoptotic Gene Apolipoprotein J (Clusterin) by B-MYB. Journal of Biological Chemistry, 2000, 275, 21055-21060.	3.4	106
43	B-MYB transactivates its own promoter through SP1-binding sites. Oncogene, 1999, 18, 1333-1339.	5.9	44
44	B-Myb protein in cellular proliferation, transcription control, and cancer: Latest developments. Journal of Cellular Physiology, 1999, 179, 245-250.	4.1	65
45	Activation of human B-MYB by cyclins. Proceedings of the National Academy of Sciences of the United States of America, 1997, 94, 532-536.	7.1	98
46	B-myb Promotes S Phase and Is a Downstream Target of the Negative Regulator p107 in Human Cells. Journal of Biological Chemistry, 1996, 271, 9363-9367.	3.4	45
47	The Retinoblastoma Family Member p107 Binds to B-MYB and Suppresses Its Autoregulatory Activity. Journal of Biological Chemistry, 1996, 271, 28738-28740.	3.4	44
48	Requirement of B- myb Function for Survival and Differentiative Potential of Human Neuroblastoma Cells. Journal of Biological Chemistry, 1995, 270, 8540-8545.	3.4	63
49	Constitutive expression of B-myb can bypass p53-induced Waf1/Cip1-mediated G1 arrest.. Proceedings of the National Academy of Sciences of the United States of America, 1994, 91, 10079-10083.	7.1	104
50	Regulation of BALB/c 3T3 fibroblast proliferation by B-myb is accompanied by selective activation of cdc2 and cyclin D1 expression.. Proceedings of the National Academy of Sciences of the United States of America, 1992, 89, 10415-10419.	7.1	103
51	Host humoral and cellular immune mechanisms in the continued suppression of Friend erythroleukemia metastases after interferon alpha/beta treatment in mice.. Journal of Experimental Medicine, 1991, 173, 1193-1203.	8.5	40
52	Hyposialylation of high-molecular-weight membrane glycoproteins parallels the loss of metastatic potential in wheat-germ agglutinin-resistant friend leukemia cells. International Journal of Cancer, 1989, 43, 126-133.	5.1	16
53	MYCN Regulates Metabolism Through Vesicular Transfer of Glycolytic Kinases. SSRN Electronic Journal, 0, , .	0.4	1